CTXR Stock Price is so consistent, can it go higher? URGENT


Citius Pharmaceuticals CTXR stock price is down 2% in the last 5 days...

Stay Ahead of the
Stock Market Game!
Subscribe to Small Cap
Exclusive for more


Biotech Is Hot And Oncomed Pharmaceuticals Inc. (NAS...
Rockwell Medical RMTI Breakout Alert
MLTX Stock Price is so consistent, can it go higher?...

Citius Pharmaceuticals CTXR stock price is down 2% in the last 5 days & volume is up 48%, but is it over for this breakout stock?

There is an old adage, “two heads are better than one”, so let’s collaborate on CTXR and compare notes.

In this in depth report, I look at 5 KPIs: Technical Analysis, Volume, News Cycle, Fundamentals & awareness campaigns. I believe the stock market is not gambling, it is also not fool proof, but I have developed a dependable system. I have found some critical components to success for CTXR, tell me what you think.

Before we get started, I like being methodical and easy to understand so I have developed a ranking system for my stocks. I call it, Alexander Goldman’s “HOT Stock Ranking!”

CA:XBC stock price

The official heat level for CTXR is, a 🔥🔥🔥 3 out of 4

Before I get ahead of myself and just jump right into this exciting breakout stock, I wanted to introduce myself.

Hello 🙋‍♂️ My name is Alexander Goldman. I have been trading small cap stocks, breakout stocks and trending stocks for 20 years now. I’m accredited for establishing the coveted HOT Stock Reporting system for breakout stocks.

To find out more about my story, CLICK HERE

[thrive_leads id=’28419′]

Citius Pharmaceuticals Company Information

Company Name: Citius Pharmaceuticals

Ticker: CTXR

Exchange: NASDAQ

Website: https://citiuspharma.com/home/default.aspx

Citius Pharmaceuticals Trust Company Summary:

Citius Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections, Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries, Halo-Lido, a corticosteroid-lidocaine topical formulation that is intended to provide anti-inflammatory and anesthetic relief to people suffering from hemorrhoids, NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome, and I/ONTAK, a protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma (CTCL). The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ.

CTXR stock price is due to News?

May 25, 2022

Announced that it intends to split the Company’s assets into two separate publicly-traded entities. Citius plans to form a new company (NewCo) focused on developing and commercializing I/ONTAK, for which a Phase 3 trial was completed in December 2021 and a biologics license application (BLA) is being planned for submission in the second half of 2022. The Company’s other pipeline assets, including Mino-Lok(R), would remain at Citius. Citius would continue to trade on the Nasdaq exchange under its current ticker CTXR. The strategic action is intended to optimize organizational resources and investment capital to support the successful execution of each development program.


CTXR Stock Price HOT Stock Grade:

The official heat level for CTXR is, a 🔥🔥🔥 3 out of 4 . Here are my takeaways on it and why it is just a 3 out of 4. Do you agree?

CTXR Trading Volume

The volume, is trading at an increase of 48% over the average which indicates a higher demand in the stock.

Trading 101: volume is measured in the number of shares traded. Traders look to volume to determine liquidity and combine changes in volume with technical indicators to make trading decisions. So, let’s take a look at the technical indicators.

CTXR Technicals

The technical analysis “chart reading”, it is bullish and has been that way since the early part of this month with a steady ascending channel.

Trading 101: Technical indicators are technical tools that help in analyzing the movement in the stock prices whether the ongoing trend is going to continue or reverse. It helps the traders to make entry and exit decisions of a particular stock. Technical indicators can be leading or lagging indicators.

CTXR News Cycle

The news, there is no significant news.

CTXR Fundamentals

The fundamentals, there is exciting financial filings associated with this stock, “265% growth”!

Trading 101: Fundamental trading is a method where a trader focuses on company-specific events to determine which stock to buy and when to buy it. Trading on fundamentals is more closely associated with a buy-and-hold strategy rather than short-term trading.

CTXR Awareness

Marketing efforts “Awareness Campaigns”, I have not found marketing efforts around the investor awareness of this company. Hence the 3 out of 4. Do you agree? Write me a line at [email protected]

Again, two heads are better than one, let’s work together to have the best trading year of our lives!

To receive my 🔥🔥🔥🔥 HOT stock as a thank you for joining our FREE newsletter, sign up today.

To find out more about my story, CLICK HERE

👇 Sign up for our newsletter to get the latest 🔥🔥🔥🔥 HOT stocks and we can compare notes!👇

[thrive_leads id=’28419′]

Stay in the lopp :

ShiftPixy PIXY up huge

ShiftPixy PIXY up huge after heavy volume after the last few days. The stock skyrocketed up over 100% in two trading days. The

Guess Who Picked Htg Molecular Diagnostics In...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Htg Molecular Diagnostics Inc (NASDAQ:HTGM) reported that Novo A/s has
Ocera Therapeutics Inc. (NASDAQ:OCRX) is Attr...
In a just published Form 13, filed with the US Securities and Exchange Commission (SEC), Ocera Therapeutics Inc. (NASDAQ:OCRX) reported that Perceptive Advisors has picked

related post

Skip to content